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Abstract
Acne conglobata is the severe form of acne, located on the face, back, and chest with 
large, painful, pus-filled cysts deep in the skin. The abscesses and sinuses result in pain, 
inflammation, and hypertrophic and atrophic scars. In this chapter, we aimed to clarify 
the pathways of acne conglobata and review the treatment options based on the literature.
Keywords: acne, nodule, severe, scar, treatment
1. Introduction
Acne conglobata (AC) is a severe chronic inflammatory disorder characterized by the presence 
of comedones, cysts, and scars on the face, back, and chest. It affects deep skin tissue and can 
result in swelling, bleeding, pain, and scarring. The clinical effects of treatment options for 
acne conglobata are often unsatisfactory because of a long course of therapy, side effects, the 
high rate of recurrence, and failure to prevent scar formation. Therefore, we aim to discuss the 
treatment options based on the literature in this chapter.
2. Clinical presentation
Acne conglobata (AC) is the uncommon and severe form of acne, characterized by large, 
tender nodules; draining sinuses; and interconnecting abscesses with seropurulent discharge. 
These lesions are generally located on the back, chest, and face. Healing of the nodules, 
abscesses usually causes hypertrophic and atrophic scars. Besides, chronic scars of AC may 
result in squamous cell carcinoma [1]. This disease is common in males more than females. 
The disease affects young adults and adolescents more frequently than elder people.
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Acne conglobata may develop owing to acute flare of existing acne, or it may occur as the 
rebound of acne that has been latent for a long time.
Synovitis, pustulosis, acne conglobata, hyperostosis, and osteitis are clinically specific inflam-
matory disorders that may be seen barely in the same patient in a syndrome known as SAPHO 
syndrome [2].
Acne conglobata may also be associated with the PAPA syndrome, which consists of pyogenic 
arthritis, acne conglobata, and pyoderma gangrenosum [3].
The primary causes of acne conglobata are still unknown. The HLA-A and HLA-B pheno-
types were evaluated in six patients with acne conglobata and hidradenitis suppurativa, in 
four of whom had HLA-B7 cross-reacting antigens and all had HLA-DRw4 [4]. Other causes 
include using anabolic steroids, withdrawal of testosterone therapy, nutrition or medications 
that contain bromine or iodine, aromatic hydrocarbons, and adrenal gland tumors which 
release large amount of androgens [5].
Acne conglobata can be malodorous, and patients may eliminate themselves from commu-
nity. Severe scarring can lead to psychological problems, such as anxiety, depression, and low 
self-esteem in many patients.
3. Treatment
Isotretinoin (13-cis retinoic acid) is an oral pharmaceutical drug primarily preferred in the 
treatment of severe nodular acne. The adverse effects are the flare of acne, cheilitis, xerosis, an 
increased susceptibility to sunburn, muscle aches, myalgias, and headaches. The patients need 
to be monitored for blood lipids and liver enzymes especially closely. It has an X category for 
pregnancy.
Isotretinoin, generally combined with prednisone, is the approved therapy for severe acne con-
globata. The recommended dosage of isotretinoin is 0.5–1.0 mg/kg/day for at least 4–5 months [6].
Gollnick et al. compared the effectiveness and safety profile of combined azelaic acid cream 
plus oral minocycline with oral isotretinoin in severe acne. Their study involved 85 patients 
with nodular papulopustular acne or acne conglobata who were treated for 6 months. 
AA cream was applied twice daily, and minocycline was taken twice daily in a dose of 50 mg 
(daily 100 mg). The doses of isotretinoin were 0.8 mg/kg for the first month, 0.7 mg/kg for the 
second month, 0.5–0.7 mg/kg for the third month, and 0.5 mg/kg for the fourth to sixth months 
per day [7].
In the 6-month course, 50 patients in the combined therapy group achieved median reduc-
tion of facial comedones, 70%; of papules and pustules, 88%; and of deep inflammatory acne 
lesions, 100%, while 35 patients in the oral isotretinoin group achieved reduction of comedones, 
83%; of papules and pustules, 97%; and of deep inflammatory acne lesions, 100%. Overall, oral 
isotretinoin was more effective than the combined treatment. The local side effects observed 
under the combination of AA and minocycline were significantly lower than that seen with 
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isotretinoin (36.5% versus 65.7%). The incidence of systemic side effects was lower under the 
combined therapy than under isotretinoin (8% versus 14.3%). They suggested that the combi-
nation of topical 20% AA cream and oral minocycline is a highly effective treatment in severe 
forms of acne, and it is better tolerated and associated with fewer risks than oral isotretinoin [7].
TNF-α is one of the important cytokines involved in the pathogenesis of acne conglobata. 
Graham et al. found that Propionibacterium acnes stimulated keratinocytes to produce interleu-
kin (IL)-1α, IL-8, and TNF-α [8]. Caillon et al. showed that levels of TNF-α and IL-8 secretion 
in peripheral blood mononuclear cells were significantly higher than in patients with acne 
vulgaris than controls [9].
As a result of the role of the TNF-α in proliferation of the immune response with the inflam-
matory infiltrate including neutrophils, lymphocytes, and histiocytes, it was hypothesized 
that acne conglobata might benefit from anti-inflammatory therapy. Notable results with 
adalimumab have been reported for the treatment of dissecting cellulitis of the scalp and 
hidradenitis suppurativa [10, 11].
On the other hand, anti-TNF therapy can stimulate paradoxical inflammatory skin conditions, of 
which the most frequent is a psoriasiform eruption. There have been three patients with Crohn’s 
disease, psoriasis vulgaris, and rheumatoid arthritis who were treated with adalimumab in the 
literature. As a result of adalimumab therapy, acneiform eruptions were occurred in these cases 
[12]. It was suggested that genetic predisposition and overlap with the primary inflammatory 
disease and autoimmune sensitivity induced interferon-α and cytokine imbalance [13].
Given the previous success reported with hidradenitis suppurativa, Shirakawa et al. consid-
ered infliximab therapy in a patient with acne conglobata and rheumatoid arthritis. The patient 
had experienced flares of the acne conglobata and side effects of oral isotretinoin. The patient 
was started on the 300 mg (3 mg/kg) of infliximab for the treatment of rheumatoid arthritis. 
The same dose was repeated at weeks 2 and 6. They observed a significant improvement in 
the size and number of his cystic lesions after the third dose. Subsequently, the same doses 
were repeated every 8 weeks and continued for at least 6 months. The patient had achieved a 
decrease in the number of lesions and pain symptoms [14].
Yiu et al. reported a patient with recalcitrant acne conglobata, who was commenced on subcu-
taneous adalimumab at 80 mg loading dose, followed by 40 mg every other week, in combina-
tion with 15 mg prednisolone. Most of the inflammatory nodules resolved within 4 weeks of 
commencing treatment with adalimumab, and this response was maintained at the 12-week 
follow-up [15].
Sand et al. reported another unresponsive patient to doxycycline, oral isotretinoin, combina-
tion of prednisolone and isotretinoin, and combination of isotretinoin and dapsone. They 
initiated monotherapy with adalimumab using an initial loading dose of 80 mg, followed by 
40 mg monthly twice. They observed a significant decrease in the size and degree of inflam-
mation of the nodular lesions 4 weeks after initial treatment and disappearance of all nodular 
lesions after 12 weeks of therapy. The patient had received continuous monotherapy with 
adalimumab, 40 mg, twice monthly for a total of 12 months, and no recurrence of acne lesions 
had appeared [16].
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Vega et al. reported a 14-year-old adolescent with recalcitrant acne conglobata on the face, 
neck, and upper chest. That patient had experienced acne fulminans and flares of severe acne 
while on the isotretinoin and prednisone therapies. Then, twice weekly injections of etan-
ercept 50 mg combined with oral isotretinoin 40 mg/d were started. They observed a clear 
improvement after 2 months of treatment. The patient had completed the isotretinoin cycle 
of 9600 mg over 8 months. They continued etanercept (50 mg/wk) 3 months more, and the 
treatment was completed after 1 year. The patient had experienced no relapse [17].
Schuttelaar et al. reported another young patient with severe acne unresponsive to other 
treatments. They started him on infliximab 5 mg/kg intravenously at 8-week interval. A total 
of eight infusions were administered. After three infusions, they did not observe neither 
new lesions nor activation of the old lesions. After 4 months, they successfully treated negli-
gible relapse of the acne with intralesional corticosteroids. No relapse was occurred at 1-year 
follow-up [18].
Electron beam processing has the ability to break the chains of DNA in living organisms and 
results in local destruction of cells. [19, 20]. The electron beam therapy delivers radiation pri-
marily to the superficial skin lesions and spares the deeper tissues from radiation. Electron 
beam radiation has been used in the treatment of mycosis fungoides, basal cell carcinoma, 
squamous cell carcinoma, and AIDS-related molluscum contagiosum lesions and Kaposi’s 
sarcoma [19–23]. The acute side effects of electron beam radiation are fatigue, itching, tanning, 
and burns. Long-term side effects include dry skin, decreased sweating, skin color changes, 
loss of scalp hair, and the development of dilated blood vessels [24].
Myers et al. reported a 53-year-old patient with acne conglobata and hidradenitis suppu-
rativa who is unresponsive to oral doxycycline, oral ampicillin, triamcinolone intralesional 
injections, topical benzoyl peroxide 5% wash, clindamycin phosphate, 1% topical solution, 
betamethasone valerate 0.1% cream, and cyclosporine 5 mg/kg per day. After these therapies, 
the patient was started a total of eight treatments of modern external beam radiation over 2 
weeks localized to the bilateral mandibular cheeks. Electron energies were 9 MeV. Daily frac-
tion sizes were 2.5 Gy for a total of 20 Gy to each side of the face. Three weeks after radiation, 
the patient reported subjective improvement in cyst size, cyst drainage, pain, and self-esteem. 
He had no significant xerosis or pigmentary abnormalities status after radiation. The patient 
had experienced no relapse at 5-month follow-up [25].
Photodynamic therapy (PDT) is a kind of phototherapy that induces selective cytotoxic 
destruction by the activation of a nontoxic light-sensitive compound with light. Up-to-date 
PDT has been used for several dermatologic diseases, such as psoriasis, cutaneous T-cell lym-
phoma, and warts [26]. PDT with topical 5-ALA damages sebaceous glands, inhibits sebum 
production, kills Propionibacterium acnes, and obstructs the follicular openings [27]. The advan-
tages of PDT include rapid efficacy, short recovery time, less destruction, and pain. Despite 
of these advantages, the local side effects of PDT are erythema, skin peeling, pain, burning, 
stinging, exfoliation, and post-inflammatory hyperpigmentation [27, 28]. It is obligatory to 
photoprotect after treatment for phototoxicity [29].
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Yang et al. investigated the clinical effects of photodynamic therapy with topical 5-aminolevu-
linic acid for facial acne conglobata. They included 75 patients with facial acne conglobata. 
They divided the patients into photodynamic therapy (PDT) group with topical 5% ami-
nolevulinic acid and red light for three times in a month and control group (n = 40) with the 
Chinese herbal medicine mask plus red light once a week. The patients were also adminis-
tered topical metronidazole, oral doxycycline, viaminate, and zinc gluconate. Efficacy was 
assessed according to symptom score, cure rate, and response rate, 2 weeks after the final 
therapy course, and time points for assessment were selected as day 0, day 10, and day 20; 
day 34 for the treatment group; and day 7, day 14, day 21, and day 35 for the control group. 
They observed that PDT was more effective for pustules and papules than control group. The 
PDT group was associated with a higher cure rate, a lower symptom score, and response rate 
than the control group. They didn’t observe systemic side effects. The erythematous swelling, 
increased number of cysts, pigmentation, and severe pain were the local side effects which 
they observed in the treatment group with PDT. They demonstrated that the treatment of 
acne conglobata with PDT is associated with a high cure rate, short treatment period, few side 
effects, and reduced scar formation [30].
Hasegawa et al. achieved to treat a case of acne conglobata by CO(2) laser ablation to remove the 
top of the sinuses and their tracts. After laser ablation, topical tretinoin therapy was also started 
simultaneously to prevent the appearance of new acne lesions. They proposed the CO(2) laser 
ablation with topical tretinoin as a powerful treatment option for acne conglobata [31]. They 
also reported another acne conglobata case, which they successfully treated by fractional laser 
after CO laser abrasion of cysts combined with topical tretinoin [32].
Liu et al. compared the effectiveness of encircling acupuncture combined with venesection and 
cupping and oral isotretinoin. A total of 26 acupuncture patients had their acupuncture courses 
once daily; venesection and cupping were applied twice a week. Patients of isotretinoin group 
were treated with oral isotretinoin 20 mg/d. The duration of study was 4 weeks. After 4 weeks, 
in acupuncture group and Western medicine group, 3 (11.5%) and 4 (15.4%) cases experienced 
remarkable relief in their signs, 14 (53.8%) and 11 (42.3%) had marked improvement, 6 (23.1%) 
and 7 (26.9%) had improvement, and 3 (11.5%) and 4 (15.4%) failed, with the effective rates 
being 88.5% and 84.6%, respectively. Overall, they didn’t observe any significant difference 
between acupuncture and oral isotretinoin (P > 0.05). In terms of lowering serum IL-6 content, 
acupuncture was found superior than oral isotretinoin (P < 0.05) [33].
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